These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 26424008)

  • 1. The garden in our gut.
    Kmietowicz Z
    BMJ; 2015 Sep; 351():h5161. PubMed ID: 26424008
    [No Abstract]   [Full Text] [Related]  

  • 2. Establishing the validity of different susceptibility testing methods to evaluate the in vitro activity of amoxicillin-clavulanate against Escherichia coli.
    María DA; María-Isabel M; María-Carmen C; Álvaro P; Jorge C; Luis MM; Francesc M; Jordi V; Adriana O; Jesús O; Rafael C
    Diagn Microbiol Infect Dis; 2016 Apr; 84(4):334-6. PubMed ID: 26830054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Susceptibility to amoxycillin-clavulanate among clinical isolates of Escherichia coli resistant to cefoxitin.
    Fernandez-Cuenca F; Martinez-Martinez L; Amblar G; Biedenbach DJ; Jones RN; Pascual A
    Clin Microbiol Infect; 2006 Feb; 12(2):197-8. PubMed ID: 16441464
    [No Abstract]   [Full Text] [Related]  

  • 4. Optimal co-amoxiclav ratios for inhibiting Escherichia coli strains with different susceptibilities to the compounds.
    Gracia M; Ponte C; Soriano F
    Int J Antimicrob Agents; 2005 Apr; 25(4):352-3. PubMed ID: 15784320
    [No Abstract]   [Full Text] [Related]  

  • 5. [Comparison of in vitro activity of ciclacillin and other penicilline(author's transl)].
    Baier R; Puppel H
    Med Klin; 1975 Jan; 70(1):24-6. PubMed ID: 164612
    [No Abstract]   [Full Text] [Related]  

  • 6. Antibiotic Resistance, Virulence Factors, Phenotyping, and Genotyping of Non-
    Amaretti A; Righini L; Candeliere F; Musmeci E; Bonvicini F; Gentilomi GA; Rossi M; Raimondi S
    Int J Mol Sci; 2020 Mar; 21(5):. PubMed ID: 32156029
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility testing of Escherichia coli isolates from urines: are we at risk of reporting false antibiotic resistance to co-amoxiclav?
    Bond A; Plumb H; Turner P
    J Antimicrob Chemother; 2012 Jun; 67(6):1557-8. PubMed ID: 22334608
    [No Abstract]   [Full Text] [Related]  

  • 8. Oral antibiotics for infections due to multidrug-resistant Gram-negative organisms.
    Glasser JS; Markelz AE; Zera WC; Beckius ML; Mende K; Murray CK
    Scand J Infect Dis; 2011 Aug; 43(8):649-51. PubMed ID: 21466257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Can the Etest correctly determine the MICs of beta-lactam and cephalosporin antibiotics for beta-lactamase-negative ampicillin-resistant Haemophilus influenzae?
    Billal DS; Hotomi M; Yamanaka N
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3463-4. PubMed ID: 17606681
    [No Abstract]   [Full Text] [Related]  

  • 10. Treatment of lower urinary tract infection caused by multidrug-resistant extended-spectrum-beta-lactamase-producing Escherichia coli with amoxicillin/clavulanate: case report and characterization of the isolate.
    Lagacé-Wiens PR; Nichol KA; Nicolle LE; DeCorby M; McCracken M; Mulvey MR; Zhanel GG
    J Antimicrob Chemother; 2006 Jun; 57(6):1262-3. PubMed ID: 16565157
    [No Abstract]   [Full Text] [Related]  

  • 11. The resistance to betalactam antibiotics of lactose-positive and lactose-negative strains of Escherichia coli.
    Janicka G; Wojciechowska D; Hareńska K; Porada J; Kłyszejko C
    Acta Microbiol Pol; 1997; 46(4):399-403. PubMed ID: 9516987
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
    López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
    Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Strain of Escherichia coli resistant to broad-spectrum cephalosporin and amoxicillin/clavulanic acid].
    Martín-Pozo A; Alós JI
    Rev Esp Quimioter; 2012 Sep; 25(3):222-3. PubMed ID: 22987271
    [No Abstract]   [Full Text] [Related]  

  • 14. [Activity of 9 beta-lactam antibiotics combined with clavulanic acid or sulbactam against the strains of broad-spectrum beta-lactamase (CTX-1) producing Enterobacteriaceae isolated at the Henri Mondor Hospital].
    Legrand P; Soussy CJ; Orsoni A; Brickley X; Duval J
    Pathol Biol (Paris); 1988 May; 36(5):425-9. PubMed ID: 3043338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In vitro susceptibilities of Escherichia coli and Klebsiella spp. to ampicillin-sulbactam and amoxicillin-clavulanic acid.
    Kacmaz B; Sultan N
    Jpn J Infect Dis; 2007 Jul; 60(4):227-9. PubMed ID: 17642541
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Resistance of Escherichia coli isolated from the urinary tract to amoxicillin-clavulanic acid and other antibiotics].
    Ferjani A; Marzouk M; Ben Moussa F; Boukadida J
    Med Mal Infect; 2010 Mar; 40(3):161-4. PubMed ID: 19616395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Urinary tract infection by multiresistant Escherichia coli and Klebsiella pneumoniae: case report].
    Martín-Pozo Á; Oteo J; Sáez D; Alós JI
    Rev Esp Quimioter; 2012 Dec; 25(4):295-6. PubMed ID: 23303263
    [No Abstract]   [Full Text] [Related]  

  • 18. Susceptibility of Escherichia coli to the amoxycillin-clavulanate combination: which recommendations should be used to provide relevant information to clinicians?
    Patry I; Hocquet D; Talon D; Plesiat P; Bertrand X
    Clin Microbiol Infect; 2005 Mar; 11(3):237-40. PubMed ID: 15715724
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activity and penetration of fosfomycin, ciprofloxacin, amoxicillin/clavulanic acid and co-trimoxazole in Escherichia coli and Pseudomonas aeruginosa biofilms.
    Rodríguez-Martínez JM; Ballesta S; Pascual A
    Int J Antimicrob Agents; 2007 Oct; 30(4):366-8. PubMed ID: 17616359
    [No Abstract]   [Full Text] [Related]  

  • 20. Prevalence and contributing factors of nonsusceptibility to imipenem or meropenem in extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli.
    Park YJ; Yu JK; Park KG; Park YG; Lee S; Kim SY; Jeong SH
    Diagn Microbiol Infect Dis; 2011 Sep; 71(1):87-9. PubMed ID: 21397426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.